Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus

The Indonesian Biomedical Journal · Vol. 15 No. 2 (2023) · hlm. 179–186

DOI
10.18585/inabj.v15i2.2212
ISSN
2085-3297, 2355-9179
Terbit
2023-04-18
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans' lower respiratory tracts and causes coronavirus disease-2019 (COVID-19). Neutralizing antibodies is one of the adaptive immune system responses that can reduce SARS-CoV-2 infection. This study aimed to develop a SARS-CoV-2 neutralization assay system using pseudo-lentivirus.METHODS: The plasmid used for pseudo-lentivirus production was characterized using restriction analysis. The gene encoding for SARS-CoV-2 spike protein was confirmed using sequencing. The transfection pseudo-lentivirus optimal condition was determined by choosing the transfection reagents and adding centrifugation step. Optimal pseudo-lentivirus infection was analysed using fluorescent assay and luciferase assay. The optimal condition of pseudo-lentivirus infection was determined by the target cell type and the number of pseudo-lentiviruses used for neutralization test. SARS-CoV-2 pseudo-lentivirus was used to detect neutralizing antibodies from serum samples.RESULTS: The plasmid used for pseudo-lentivirus production was characterized and confirmed to have no mutations. Lipofectamine 2000 reagent generated pseudo-lentivirus with a higher ability to infect target cells, as indicated by a percentage green fluorescent protein (GFP) of 12.68%. Pseudo-lentivirus centrifuged obtained more stable results in luciferase expression. Optimal pseudo-lentivirus infection conditions were obtained using puromycin-selected HEK 293T-ACE2 cells as target cells. The number of pseudo-lentiviruses used in the neutralization assay system was multiplicity of infection (MOI) 0.075. Serum A samples with a 1:10 dilution had the highest neutralizing antibody activity.CONCLUSION: This study shows that SARS-CoV-2 neutralization assay system using pseudo-lentivirus successfully detected neutralizing antibodies in human serum, which were indicated by a decrease in the percentage of pseudo-lentivirus infections.KEYWORDS: COVID-19, neutralizing antibody, neutralization assay, pseudo-lentivirus, SARS-COV-2

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 219 tautan kepenulisan bersama · 103 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Bandung Institute of Technology
  • National Research and Innovation Agency
  • Center for Infectious Disease Education and Research, The University of Osaka
  • Indonesian Institute of Sciences
  • Atma Jaya Catholic University of Indonesia
  • PT Bio Farma (Indonesia)
  • Universitas Gadjah Mada
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
DEBBIE SOEFIE RETNONINGRUMBandung Institute of Technology6
Catur RianiBandung Institute of Technology4
AnindyajatiAfiliasi tidak diketahui3
Ernawati Arifin Giri-RachmanBandung Institute of Technology3
Salma Aulia AfifahBandung Institute of Technology3
Raymond R. TjandrawinataAtma Jaya Catholic University of Indonesia2
Hariyatun HariyatunIndonesian Institute of Sciences2
Yana RubiyanaNational Research and Innovation Agency2
Popi Hadi WisnuwardhaniNational Research and Innovation Agency2
Ratih Asmana NingrumNational Research and Innovation Agency2
Fitri Aulia PermatasariBandung Institute of Technology2
Ferry IskandarBandung Institute of Technology2
Dian Fitria AgustiyantiNational Research and Innovation Agency2
Marissa AngelinaNational Research and Innovation Agency2
Andri WardianaNational Research and Innovation Agency2
Azzania FibrianiBandung Institute of Technology2
Patricia Gita NaullyBandung Institute of Technology2
Neni NurainyPT Bio Farma (Indonesia)2
Elvi RestiawatyBandung Institute of Technology2
Wardono NiloperbowoBandung Institute of Technology2
Rukman HertadiBandung Institute of Technology2
Novia Syari IntanBandung Institute of Technology2
Putri Ayu FajarBandung Institute of Technology2
Gladys Emmanuella Putri WojciechowskaBandung Institute of Technology2
Armini SyamsidiBandung Institute of Technology1
Anindyajati AnindyajatiUniversitas Gadjah Mada1
Desriani DesrianiIndonesian Institute of Sciences1
Audrey Angelina Putri TaharuddinBandung Institute of Technology1
Nicholas YamahokiBandung Institute of Technology1
Rebecca StephanieBandung Institute of Technology1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">SARS-CoV-2 Neutralization Assay System using Pseudo-lentivirus</dc:title><dc:creator>Anastasia Armimi</dc:creator><dc:creator>Afina Firdaus Syuaib</dc:creator><dc:creator>Katherine Vanya</dc:creator><dc:creator>Marselina Irasonia Tan</dc:creator><dc:creator>Dessy Natalia</dc:creator><dc:creator>David Virya Chen</dc:creator><dc:creator>Chikako Ono</dc:creator><dc:creator>Yoshiharu Matsuura</dc:creator><dc:creator>Anita Artarini</dc:creator><dc:creator>Ernawati Arifin Giri-Rachman</dc:creator><dc:subject>SARS-CoV-2</dc:subject><dc:subject>neutralizing antibodies</dc:subject><dc:subject>neutralization test</dc:subject><dc:subject>COVID-19 pandemic</dc:subject><dc:subject>spike protein</dc:subject><dc:subject>multiplicity of infection</dc:subject><dc:subject>serum antibody detection</dc:subject><dc:description xml:lang="en">BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects humans' lower respiratory tracts and causes coronavirus disease-2019 (COVID-19). Neutralizing antibodies is one of the adaptive immune system responses that can reduce SARS-CoV-2 infection. This study aimed to develop a SARS-CoV-2 neutralization assay system using pseudo-lentivirus.METHODS: The plasmid used for pseudo-lentivirus production was characterized using restriction analysis. The gene encoding for SARS-CoV-2 spike protein was confirmed using sequencing. The transfection pseudo-lentivirus optimal condition was determined by choosing the transfection reagents and adding centrifugation step. Optimal pseudo-lentivirus infection was analysed using fluorescent assay and luciferase assay. The optimal condition of pseudo-lentivirus infection was determined by the target cell type and the number of pseudo-lentiviruses used for neutralization test. SARS-CoV-2 pseudo-lentivirus was used to detect neutralizing antibodies from serum samples.RESULTS: The plasmid used for pseudo-lentivirus production was characterized and confirmed to have no mutations. Lipofectamine 2000 reagent generated pseudo-lentivirus with a higher ability to infect target cells, as indicated by a percentage green fluorescent protein (GFP) of 12.68%. Pseudo-lentivirus centrifuged obtained more stable results in luciferase expression. Optimal pseudo-lentivirus infection conditions were obtained using puromycin-selected HEK 293T-ACE2 cells as target cells. The number of pseudo-lentiviruses used in the neutralization assay system was multiplicity of infection (MOI) 0.075. Serum A samples with a 1:10 dilution had the highest neutralizing antibody activity.CONCLUSION: This study shows that SARS-CoV-2 neutralization assay system using pseudo-lentivirus successfully detected neutralizing antibodies in human serum, which were indicated by a decrease in the percentage of pseudo-lentivirus infections.KEYWORDS: COVID-19, neutralizing antibody, neutralization assay, pseudo-lentivirus, SARS-COV-2</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2023-04-18</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v15i2.2212</dc:identifier><dc:identifier>10.18585/inabj.v15i2.2212</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 15 No 2 (2023); 179-186</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/2212/636</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>